Scientific
MK5 Microarray Data

Affected Genes - Ontology Breakdown - Gene Enrichment - Proteome Analysis
These are the micro-array results of a differential gene expression microarray experiments and the subsequent analysis steps performed on them. The up/down- regulation ratio was obtained by measuring WT cells against MK5 activated cells. See material and methods for technical information as well as the data usage policy.
MK5 Proteome Analysis

Table 3: Type II network, divided ranks. This table presents the output of the simulation of a type-II network in which we relied on the high confidence interactions and micro-array results. The output of the micro-array was then ranked and these ranks used as input into the network simulation. After performing two such simulations (one for the MK5 off and one for the MK5 on microarray output), we divided the ranks and sorted the results accordingly. The output of this technique is a collection of proteins that cluster naturally together.
Navigation/Query Panel:
Click on the attribute name to hide/unhide it. The green arrows can be used to shift columns left/right. Exact word match is written as =..., regular expressions can be matched with ~.... To select all values larger or equal than use >.... This would be <... for values smaller or equal than. To select all values within a specific range use [...,...].
Rank Gene Hugo description Value Type Network Comparison Type Interaction Map Filtered red green network_comparison
Results: HTML CSV LaTeX
Showing element 1 to 50 of 3228 in total
Value Type: Ranked
Network Comparison Type: Divided
Interaction Map: High confidence
Filtered: 1

\def\wcA{0.14285714285714\textwidth}
\def\wcB{0.14285714285714\textwidth}
\def\wcC{0.14285714285714\textwidth}
\def\wcD{0.14285714285714\textwidth}
\def\wcE{0.14285714285714\textwidth}
\def\wcF{0.14285714285714\textwidth}
\begin{longtable}{|c|c|c|c|c|c|}
\hline
\parbox{\wcA}{\vspace{3pt}\noindent
Rank\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
Hugo\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
description\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
red\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
green\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
network\_comparison\vspace{3pt}}\\
\hline
\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
UBAC1\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
putative glialblastoma cell differentiation-related; putative glialblastoma cell differentiation-related protein. [source:refseq;acc:nm\_016172]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
10\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
24\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
2.4\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
mannosyl-oligosaccharide 1,2-alpha-mannosidase ib (ec 3.2.1.113) (processing alpha-1,2-mannosidase ib) (alpha-1,2-mannosidase ib) (mannosidase alpha class 1a member 2). [source:swissprot;acc:o60476]\vspace{3pt}}&\multirow{5}{*}{\parbox{\wcD}{\vspace{3pt}\noindent
15\vspace{3pt}}}&\multirow{5}{*}{\parbox{\wcE}{\vspace{3pt}\noindent
28\vspace{3pt}}}&\multirow{5}{*}{\parbox{\wcF}{\vspace{3pt}\noindent
1.86667\vspace{3pt}}}\\\cline{1-3}
\parbox{\wcA}{\vspace{3pt}\noindent
3\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
PSCD1\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
cytohesin 1 (sec7 homolog b2-1). [source:swissprot;acc:q15438]\vspace{3pt}}&&&\\\cline{1-3}
\parbox{\wcA}{\vspace{3pt}\noindent
4\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
PSCD2\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
cytohesin 2 (arf nucleotide-binding site opener) (arno protein) (arf exchange factor). [source:swissprot;acc:q99418]\vspace{3pt}}&&&\\\cline{1-3}
\parbox{\wcA}{\vspace{3pt}\noindent
5\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
PSCD4\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
cytohesin 4. [source:swissprot;acc:q9uia0]\vspace{3pt}}&&&\\\cline{1-3}
\parbox{\wcA}{\vspace{3pt}\noindent
6\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
PSCD3\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
cytohesin 3 (arf nucleotide-binding site opener 3) (arno3 protein) (general receptor of phosphoinositides 1) (grp1). [source:swissprot;acc:o43739]\vspace{3pt}}&&&\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
7\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
HLX\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
homeobox protein hlx1 (homeobox protein hb24). [source:swissprot;acc:q14774]\vspace{3pt}}&\multirow{2}{*}{\parbox{\wcD}{\vspace{3pt}\noindent
215\vspace{3pt}}}&\multirow{2}{*}{\parbox{\wcE}{\vspace{3pt}\noindent
322\vspace{3pt}}}&\multirow{2}{*}{\parbox{\wcF}{\vspace{3pt}\noindent
1.49767\vspace{3pt}}}\\\cline{1-3}
\parbox{\wcA}{\vspace{3pt}\noindent
8\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
HBS1L\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
hbs1-like. [source:refseq;acc:nm\_006620]\vspace{3pt}}&&&\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
9\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
XAB1\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
xpa binding protein 1; mbd2 interactor protein; putative atp(gtp)-binding protein. [source:refseq;acc:nm\_007266]\vspace{3pt}}&\multirow{2}{*}{\parbox{\wcD}{\vspace{3pt}\noindent
212\vspace{3pt}}}&\multirow{2}{*}{\parbox{\wcE}{\vspace{3pt}\noindent
309\vspace{3pt}}}&\multirow{2}{*}{\parbox{\wcF}{\vspace{3pt}\noindent
1.45755\vspace{3pt}}}\\\cline{1-3}
\parbox{\wcA}{\vspace{3pt}\noindent
10\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
ATPBD1C\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
protein x 0004. [source:refseq;acc:nm\_016301]\vspace{3pt}}&&&\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
11\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
RINT1\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
rad50-interacting protein 1. [source:refseq;acc:nm\_021930]\vspace{3pt}}&\multirow{2}{*}{\parbox{\wcD}{\vspace{3pt}\noindent
337\vspace{3pt}}}&\multirow{2}{*}{\parbox{\wcE}{\vspace{3pt}\noindent
232\vspace{3pt}}}&\multirow{2}{*}{\parbox{\wcF}{\vspace{3pt}\noindent
1.45259\vspace{3pt}}}\\\cline{1-3}
\parbox{\wcA}{\vspace{3pt}\noindent
12\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
RHOBTB2\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
rho-related btb domain-containing protein 2 (deleted in breast cancer 2 gene protein) (p83). [source:swissprot;acc:q9byz6]\vspace{3pt}}&&&\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
13\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
UFC1\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
protein cgi-126 (protein hspc155). [source:swissprot;acc:q9y3c8]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
288.754\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
212.554\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
1.3585\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
14\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
ATG4A\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
cysteine endopeptidase aut-like 2 isoform a; autophagy-related cysteine endopeptidase 2; autophagin 2. [source:refseq;acc:nm\_052936]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
56.6768\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
75.3531\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
1.32952\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
15\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
MAP1LC3B\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
microtubule-associated proteins 1a/1b light chain 3b (map1a/map1b lc3 b) (map1a/1b light chain 3 b). [source:swissprot;acc:q9gzq8]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
56.7244\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
75.3948\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
1.32914\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
16\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
MAP1LC3A\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
microtubule-associated proteins 1a/1b light chain 3a (map1a/map1b lc3 a) (map1a/1b light chain 3 a). [source:swissprot;acc:q9h492]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
56.7252\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
75.3954\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
1.32913\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
17\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
ATG4B\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
cysteine endopeptidase aut-like isoform b. [source:refseq;acc:nm\_178326]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
56.7841\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
75.447\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
1.32866\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
18\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
GBE1\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
1,4-alpha-glucan branching enzyme (ec 2.4.1.18) (glycogen branching enzyme) (brancher enzyme). [source:swissprot;acc:q04446]\vspace{3pt}}&\multirow{5}{*}{\parbox{\wcD}{\vspace{3pt}\noindent
185.678\vspace{3pt}}}&\multirow{5}{*}{\parbox{\wcE}{\vspace{3pt}\noindent
245.247\vspace{3pt}}}&\multirow{5}{*}{\parbox{\wcF}{\vspace{3pt}\noindent
1.32082\vspace{3pt}}}\\\cline{1-3}
\parbox{\wcA}{\vspace{3pt}\noindent
19\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
PYGB\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
glycogen phosphorylase, brain form (ec 2.4.1.1). [source:swissprot;acc:p11216]\vspace{3pt}}&&&\\\cline{1-3}
\parbox{\wcA}{\vspace{3pt}\noindent
20\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
PYGL\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
glycogen phosphorylase, liver form (ec 2.4.1.1). [source:swissprot;acc:p06737]\vspace{3pt}}&&&\\\cline{1-3}
\parbox{\wcA}{\vspace{3pt}\noindent
21\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
MYO15A\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
myosin xv (unconventional myosin-15). [source:swissprot;acc:q9ukn7]\vspace{3pt}}&&&\\\cline{1-3}
\parbox{\wcA}{\vspace{3pt}\noindent
22\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
PYGM\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
glycogen phosphorylase, muscle form (ec 2.4.1.1) (myophosphorylase). [source:swissprot;acc:p11217]\vspace{3pt}}&&&\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
23\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
MRPS17\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
28s ribosomal protein s17, mitochondrial precursor (mrp-s17) (hspc011). [source:swissprot;acc:q9y2r5]\vspace{3pt}}&\multirow{5}{*}{\parbox{\wcD}{\vspace{3pt}\noindent
58\vspace{3pt}}}&\multirow{5}{*}{\parbox{\wcE}{\vspace{3pt}\noindent
44\vspace{3pt}}}&\multirow{5}{*}{\parbox{\wcF}{\vspace{3pt}\noindent
1.31818\vspace{3pt}}}\\\cline{1-3}
\parbox{\wcA}{\vspace{3pt}\noindent
24\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
PANK1\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
pantothenate kinase 1 (ec 2.7.1.33) (pantothenic acid kinase 1) (hpank1) (hpank). [source:swissprot;acc:q8te04]\vspace{3pt}}&&&\\\cline{1-3}
\parbox{\wcA}{\vspace{3pt}\noindent
25\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
PANK2\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
pantothenate kinase 2, mitochondrial precursor (ec 2.7.1.33) (pantothenic acid kinase 2) (hpank2). [source:swissprot;acc:q9bz23]\vspace{3pt}}&&&\\\cline{1-3}
\parbox{\wcA}{\vspace{3pt}\noindent
26\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
PANK3\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
pantothenate kinase 3 (ec 2.7.1.33) (pantothenic acid kinase 3) (hpank3). [source:swissprot;acc:q9h999]\vspace{3pt}}&&&\\\cline{1-3}
\parbox{\wcA}{\vspace{3pt}\noindent
27\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
SLC25A43\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
mitochondrial solute carrier protein. [source:refseq;acc:nm\_145305]\vspace{3pt}}&&&\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
28\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
ATF3\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
cyclic-amp-dependent transcription factor atf-3 (activating transcription factor 3). [source:swissprot;acc:p18847]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
201.949\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
153.671\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
1.31416\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
29\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
PPP2R2D\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
uncharacterized hematopoietic stem/progenitor cells protein mds026. [source:sptrembl;acc:q9nz48]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
187.458\vspace{3pt}}&\multirow{2}{*}{\parbox{\wcE}{\vspace{3pt}\noindent
243.678\vspace{3pt}}}&\multirow{2}{*}{\parbox{\wcF}{\vspace{3pt}\noindent
1.29991\vspace{3pt}}}\\\cline{1-4}
\parbox{\wcA}{\vspace{3pt}\noindent
30\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
serine/threonine protein phosphatase 2a, 55 kda regulatory subunit b, alpha isoform (pp2a, subunit b, b-alpha isoform) (pp2a, subunit b, b55-alpha isoform) (pp2a, subunit b, pr55-alpha isoform) (pp2a, subunit b, r2-alpha isoform). [source:swissprot;acc:q00007]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
187.457\vspace{3pt}}&&\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
31\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
PPP2R2B\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
serine/threonine protein phosphatase 2a, 55 kda regulatory subunit b, beta isoform (pp2a, subunit b, b-beta isoform) (pp2a, subunit b, b55- beta isoform) (pp2a, subunit b, pr55-beta isoform) (pp2a, subunit b, r2-beta isoform). [source:swissprot;acc:q00005]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
187.458\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
243.677\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
1.2999\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
32\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
PPP2R2C\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
serine/threonine protein phosphatase 2a, 55 kda regulatory subunit b, gamma isoform (pp2a, subunit b, b-gamma isoform) (pp2a, subunit b, b55-gamma isoform) (pp2a, subunit b, pr55-gamma isoform) (pp2a, subunit b, r2-gamma isoform) (imypno1). [source:swissprot;acc:q9y2t4]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
187.462\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
243.673\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
1.29985\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
33\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
PPP2R1B\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
serine/threonine protein phosphatase 2a, 65 kda regulatory subunit a, beta isoform (pp2a, subunit a, pr65-beta isoform) (pp2a, subunit a, r1-beta isoform). [source:swissprot;acc:p30154]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
188.688\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
242.742\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
1.28647\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
34\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
PPP2R1A\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
serine/threonine protein phosphatase 2a, 65 kda regulatory subunit a, alpha isoform (pp2a, subunit a, pr65-alpha isoform) (pp2a, subunit a, r1-alpha isoform) (medium tumor antigen-associated 61 kda protein). [source:swissprot;acc:p30153]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
189.07\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
242.453\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
1.28235\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
35\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
NFYC\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
nuclear transcription factor y subunit gamma (nf-y protein chain c) (nuclear factor yc) (nf-yc) (ccaat-binding transcription factor subunit c) (cbf-c) (transactivator hsm-1/2). [source:swissprot;acc:q13952]\vspace{3pt}}&\multirow{2}{*}{\parbox{\wcD}{\vspace{3pt}\noindent
260.532\vspace{3pt}}}&\multirow{2}{*}{\parbox{\wcE}{\vspace{3pt}\noindent
204.309\vspace{3pt}}}&\multirow{2}{*}{\parbox{\wcF}{\vspace{3pt}\noindent
1.27519\vspace{3pt}}}\\\cline{1-3}
\parbox{\wcA}{\vspace{3pt}\noindent
36\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
NFYA\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
ccaat-binding transcription factor subunit b (cbf-b) (nf-y protein chain a) (nf-ya) (caat-box dna binding protein subunit a). [source:swissprot;acc:p23511]\vspace{3pt}}&&&\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
37\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
PPP1R14A\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
protein phosphatase 1, regulatory (inhibitor) subunit 14a; 17-kda pkc-potentiated inhibitory protein of pp1. [source:refseq;acc:nm\_033256]\vspace{3pt}}&\multirow{5}{*}{\parbox{\wcD}{\vspace{3pt}\noindent
322\vspace{3pt}}}&\multirow{5}{*}{\parbox{\wcE}{\vspace{3pt}\noindent
253\vspace{3pt}}}&\multirow{5}{*}{\parbox{\wcF}{\vspace{3pt}\noindent
1.27273\vspace{3pt}}}\\\cline{1-3}
\parbox{\wcA}{\vspace{3pt}\noindent
38\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
MFAP4\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
microfibril-associated glycoprotein 4 precursor. [source:swissprot;acc:p55083]\vspace{3pt}}&&&\\\cline{1-3}
\parbox{\wcA}{\vspace{3pt}\noindent
39\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
PPP1R14D\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
protein phosphatase 1, regulatory subunit 14d; pkc-dependent pp1 inhibitory protein. [source:refseq;acc:nm\_017726]\vspace{3pt}}&&&\\\cline{1-3}
\parbox{\wcA}{\vspace{3pt}\noindent
40\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
FCN2\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
ficolin 2 precursor (collagen/fibrinogen domain-containing protein 2) (ficolin-b) (ficolin b) (serum lectin p35) (ebp-37) (hucolin) (l- ficolin). [source:swissprot;acc:q15485]\vspace{3pt}}&&&\\\cline{1-3}
\parbox{\wcA}{\vspace{3pt}\noindent
41\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
protein phosphatase 1, regulatory (inhibitor) subunit 14c; serologically defined breast cancer antigen ny-br-81; pkc-potentiated pp1 inhibitory protein. [source:refseq;acc:nm\_030949]\vspace{3pt}}&&&\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
42\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
FOS\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
proto-oncogene protein c-fos (cellular oncogene fos) (g0/g1 switch regulatory protein 7). [source:swissprot;acc:p01100]\vspace{3pt}}&\multirow{4}{*}{\parbox{\wcD}{\vspace{3pt}\noindent
204.641\vspace{3pt}}}&\multirow{2}{*}{\parbox{\wcE}{\vspace{3pt}\noindent
160.957\vspace{3pt}}}&\multirow{2}{*}{\parbox{\wcF}{\vspace{3pt}\noindent
1.2714\vspace{3pt}}}\\\cline{1-3}
\parbox{\wcA}{\vspace{3pt}\noindent
43\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
jun dimerization protein. [source:refseq;acc:nm\_130469]\vspace{3pt}}&&&\\\cline{1-3}\cline{5-6}
\parbox{\wcA}{\vspace{3pt}\noindent
44\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
FOSL2\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
fos-related antigen 2. [source:swissprot;acc:p15408]\vspace{3pt}}&&\parbox{\wcE}{\vspace{3pt}\noindent
161.046\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
1.2707\vspace{3pt}}\\\cline{1-3}\cline{5-6}
\parbox{\wcA}{\vspace{3pt}\noindent
45\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
FOSB\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
protein fosb (g0/g1 switch regulatory protein 3). [source:swissprot;acc:p53539]\vspace{3pt}}&&\parbox{\wcE}{\vspace{3pt}\noindent
161.051\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
1.27066\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
46\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
FOSL1\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
fos-related antigen 1 (fra-1). [source:swissprot;acc:p15407]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
204.642\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
161.068\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
1.27053\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
47\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
TMEM132A\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
gbp protein isoform a. [source:refseq;acc:nm\_017870]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
325.586\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
256.492\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
1.26938\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
48\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
GABARAP\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
gaba(a) receptor-associated protein; gaba(a)-receptor-associated protein. [source:refseq;acc:nm\_007278]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
65.4586\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
83.0461\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
1.26868\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
49\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
ARRB2\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
beta-arrestin 2 (arrestin, beta 2). [source:swissprot;acc:p32121]\vspace{3pt}}&\multirow{2}{*}{\parbox{\wcD}{\vspace{3pt}\noindent
133\vspace{3pt}}}&\multirow{2}{*}{\parbox{\wcE}{\vspace{3pt}\noindent
105\vspace{3pt}}}&\multirow{2}{*}{\parbox{\wcF}{\vspace{3pt}\noindent
1.26667\vspace{3pt}}}\\\cline{1-3}
\parbox{\wcA}{\vspace{3pt}\noindent
50\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
ARRB1\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
beta-arrestin 1 (arrestin, beta 1). [source:swissprot;acc:p49407]\vspace{3pt}}&&&\\\hline
nd{longtable}

Legend:
- Rank is the rank after comparing the two networks

 - Gene is the ensembl human gene identifier measured by 1 or more probes on the microarray

 - Hugo is the HGNC identifier if it exists

 - Value Type describes how the microarray measurement was processed. Ranked indicates that we sorted all measurements and use the rank as red and green value. Measured is the normal measurement. Squared and Rooted are the square and square root respecitcely. This might be valueable to compensate for non linear light distributions.

 - Network Comparison Type describes whether we divided the red and green types or whether we sutractcted them

 - Interaction Map specifies whether we used only the hig hconfidence protein-protein interactions or also included the low confidence interactions.

 - Filtered specifies whether we only included the high confidence microarry measurements or not.
- http://analysis.yellowcouch.org/